OphSourceHomeJournal CollectionOphSource ShopEvents
Journal Home
Search for

Volume 106, Issue 11, Pages 2047-2053 (1 November 1999)


View previous. 9 of 39 View next.

The impact of the optic neuritis treatment trial on the practices of ophthalmologists and neurologists

Jonathan D Trobe, MDCorresponding Author Information12email address, Pamela C Sieving, MS1, Kenneth E Guire, MS3, A.Mark Fendrick, MD4

Received 5 February 1999; accepted 6 July 1999.

Abstract 

Objective

To determine whether the Optic Neuritis Treatment Trial (ONTT) results have altered the practice patterns of ophthalmologists and neurologists.

Design

Mail survey.

Participants

A random sample of 987 ophthalmologists and 900 neurologists practicing in the United States were mailed a questionnaire that inquired into decision-making with regard to management of optic neuritis before and after the publication of the ONTT results.

Main outcome measures

Responses received from 202 ophthalmologists and 244 neurologists, a response rate of 47%.

Results

Following the ONTT reports, nearly all ophthalmologists and neurologists have reduced their use of oral prednisone alone, substituting a regimen that includes intravenous methylprednisolone. A large proportion of practitioners in both specialties mistakenly believe that intravenous methylprednisolone treatment improves final visual outcome. Only 7% of neurologists and 36% of ophthalmologists (P = 0.0001) are adhering to the ONTT suggestion to use magnetic resonance imaging as a basis for initiating treatment.

Conclusions

The ONTT has led to a dramatic reduction in the use of oral prednisone without a preceding course of intravenous methylprednisolone in the treatment of acute optic neuritis. Ophthalmologists and neurologists have changed some of their practices without fully understanding the results of the ONTT.

Manuscript no. 99070.

1 Department of Ophthalmology, W.K. Kellogg Eye Center, School of Medicine, University of Michigan, Ann Arbor, Michigan USA

2 Department of Neurology, W.K. Kellogg Eye Center, School of Medicine, University of Michigan, Ann Arbor, Michigan USA

3 Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan USA

4 Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan USA

Corresponding Author InformationReprint requests to Jonathan D. Trobe, MD, W.K. Kellogg Eye Center, 1000 Wall Street, Ann Arbor, MI 48105USA

 Supported through a cooperative agreement from the National Eye Institute of the National Institutes of Health, EY 09435.

PII: S0161-6420(99)90482-7

doi:10.1016/S0161-6420(99)90482-7


View previous. 9 of 39 View next.